Inhibrx Biosciences/$INBX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Inhibrx Biosciences

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Ticker

$INBX
Sector
Health
Primary listing
NASDAQ

Employees

159
Headquarters
La Jolla, United States
Website
inhibrx.com

INBX Metrics

BasicAdvanced
$403M
-
-$10.58
-
-

What the Analysts think about INBX

Analyst ratings (Buy, Hold, Sell) for Inhibrx Biosciences stock.

Bulls say / Bears say

The Phase 2 registration trial for ozekibart (INBRX-109) in unresectable or metastatic conventional chondrosarcoma finished enrolling all patients in July 2025, setting up the company to deliver key progression-free survival results by the end of October 2025. (PRNewswire)
As of June 30, 2025, Inhibrx had $186.6 million in cash and cash equivalents, enough to support ongoing clinical programs through expected data announcements in late 2025. (PRNewswire)
In April 2025, Inhibrx expanded its leadership by bringing in Dr. Carlos Bais as Chief Scientific Officer and promoting David Matly to President, strengthening the company for late-stage development and future commercialization. (Investing.com)
Inhibrx posted a net loss of $28.7 million for Q2 2025, after already losing $43.3 million in Q1 2025, showing that the business remains unprofitable. (PRNewswire) (PRNewswire)
Cash reserves fell by $29.9 million, from $216.5 million as of March 31, 2025, to $186.6 million as of June 30, 2025, pointing to a high cash burn that might require additional funding. (PRNewswire)
Key data releases for INBRX-109 in chondrosarcoma and INBRX-106 in head and neck cancer and non-small cell lung cancer aren't expected until Q3 and Q4 2025, leaving the company's valuation highly dependent on binary clinical outcomes in the coming months. (PRNewswire)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

INBX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

INBX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INBX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs